Looking for treatment? Same-day visits usually available. No insurance required.
What is the difference between methadone and Suboxone?
Methadone is a full opioid agonist dispensed through clinics, while Suboxone (buprenorphine) is a partial agonist that can be prescribed in office-based or telehealth settings. Both treat opioid use disorder, but differ in access, safety profile, and daily structure.
How they work
Different mechanisms, different effects.
Methadone
A full opioid agonist. Methadone fully activates opioid receptors and is used to suppress withdrawal and cravings by acting at the same receptors as other opioids. Because it is a full agonist, methadone carries a higher risk of overdose than buprenorphine, particularly at initiation, and requires careful dose titration. Its half-life is long and variable (24–36 hours or longer), which makes accumulation a clinical concern.
Buprenorphine (Suboxone)
A partial opioid agonist. Buprenorphine activates opioid receptors but to a lesser extent than full agonists. It has a ceiling effect on respiratory depression, contributing to a more favorable safety profile. Its high receptor binding affinity gives it a blocking effect against other opioids.
Access and prescribing
How patients access each medication is fundamentally different.
Methadone for OUD
Methadone for opioid use disorder must be dispensed through federally licensed opioid treatment programs (OTPs) — methadone clinics. Patients typically attend daily for observed dosing, particularly in early treatment. Take-home doses are earned over time according to federal and state regulations. This creates a significant access barrier for many patients — particularly those in rural areas, those with employment constraints, or those with transportation limitations.
Buprenorphine
Buprenorphine for OUD can be prescribed by any qualified physician in an office-based setting and dispensed through any licensed pharmacy. Telehealth prescribing may be permitted under current federal rules, depending on regulatory requirements and clinical circumstances. Patients do not need to attend a specialized clinic and can manage their medication at home.
Clinical considerations
What the evidence shows.
Both medications are effective for opioid use disorder. Large comparative studies, including a widely cited JAMA Network Open study published in 2020, found that both buprenorphine and methadone were associated with better outcomes than non-medication treatment pathways.1
In some studies, methadone has shown somewhat higher retention — partly because its full agonist effect is more familiar to patients coming from full opioid use, and partly because the daily clinic attendance itself creates a structured environment. Buprenorphine shows better safety margins and far better accessibility.
The choice between them is an individualized clinical decision rather than a simple hierarchy.
1 Wakeman SE, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 2020. pubmed.ncbi.nlm.nih.gov
Sources
Where this information comes from.
Wakeman et al. — Comparative Effectiveness (2020)
Large comparative study showing both buprenorphine and methadone substantially outperform non-medication approaches.
Federal overview of methadone for OUD including access regulations and OTP requirements.
FDA: Medications for Opioid Use Disorder
Comparison of approved medications for OUD including mechanism and regulatory status.
ASAM National Practice Guideline (2020)
Clinical guidance on choosing between buprenorphine, methadone, and naltrexone for OUD.
MyStreetHealth serves
Virginia · Maryland · Washington DC · West Virginia · Ohio
Related
Common questions
Frequently asked
Why do some patients stay on methadone instead of switching?
Methadone may be preferred when higher doses are needed, when prior buprenorphine treatment was not effective, or when the structure of a daily clinic supports recovery. It is not inferior — it is a different option for different situations.
Which has more drug interactions?
Methadone has a more complex interaction profile, including QTc prolongation risk, compared to buprenorphine. Both require physician oversight.
Can you take both at the same time?
No. They should not be taken together. Switching from one to the other requires a careful transition plan guided by a physician.
